Advertisement
Advertisement
IVVD
Invivyd, Inc. Common Stock
0.54
USDSponsored
-0.05
-8.01%
Jul 31, 15:59 UTC -4
Closed
After-Market
0.54
0.00
+0.56%
IVVD Earnings Reports
Positive Surprise Ratio
IVVD beat 10 of 20 last estimates.
50%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.69M
/-$0.10
Implied change from Q1 26 (Revenue/ EPS)
+6.87%
/-23.08%
Implied change from Q2 25 (Revenue/ EPS)
+24.62%
/-16.67%
Invivyd, Inc. Common Stock earnings per share and revenue
On May 14, 2026, IVVD reported earnings of -0.13 USD per share (EPS) for Q1 26, missing the estimate of -0.07 USD, resulting in a -73.80% surprise. Revenue reached 13.74 million, compared to an expected 18.41 million, with a -25.35% difference. The market reacted with a -21.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 14.69 million USD, implying an decrease of -23.08% EPS, and increase of 6.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
Myriad Genetics Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.25
Surprise
-323.73%
Crescent Biopharma, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.74
Surprise
+8.74%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.20%
Regeneron Pharmaceuticals Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$10.46
Actual
$14.29
Surprise
+36.51%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.42
Actual
$0.92
Surprise
+116.37%
FAQ
What were Invivyd, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Invivyd, Inc. Common Stock reported EPS of -$0.13, missing estimates by -73.8%, and revenue of $13.74M, -25.35% below expectations.
How did the market react to Invivyd, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -21.09%, changed from $1.47 before the earnings release to $1.16 the day after.
When is Invivyd, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Invivyd, Inc. Common Stock's next earnings report?
Based on 5
analysts, Invivyd, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $14.69M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement